Respiratory medicine · 2025
Adverse pregnancy outcomes and lung function later in life: The CARDIA lung study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jing Gennie, Colangelo Laura A, Meislin Rachel, Khan Sadiya S, Catov Janet, Lane Abbi, Gunderson Erica P, Hanson Corrine, Kalhan Ravi, Bose Sonali
Аннотация
BACKGROUND: Pregnancy events are linked to future maternal health, although relationships between adverse pregnancy outcomes (APOs) and maternal respiratory health are unknown.
METHODS: This is a secondary analysis of CARDIA, a multicenter cohort study. We included all women who had delivered a live infant. APOs were defined as a history of ever having a small-for-gestational-age infant, preterm birth, gestational diabetes mellitus, or hypertensive disorder of pregnancy. Women were categorized as having no, one or >1 pregnancy with any APOs. Outcomes included year 30 lung function, annual change in lung function from year 20-30 and presence of radiographic emphysema at year 25. Adjusted linear regression was used to evaluate associations between APO category and percent predicted forced expiratory volume in 1 s (FEV1) (ppFEV1), forced vital capacity (FVC) (ppFVC) and annual rate of decline in FEV1 and FVC from year 20-30.
RESULTS: Among 657 women, those with >1 pregnancy with APOs had a significantly lower year 30 ppFEV1 and greater annual decline in FEV1, compared to those without APOs (β co-efficient -2.45 %; 95 % CI, -4.87 to -0.03, and -6.67 ml/year; 95 % CI, -12.90 to -0.44, respectively). However, after adjustment for parity, findings were no longer statistically significant, raising the question of whether multiparity or recurrent pregnancies with APOs may be driving associations with lower FEV1.
CONCLUSIONS: A history of APOs may represent a novel, early indicator of worse lifetime maternal respiratory health, although larger studies accounting for multiparity and other important confounders are needed to confirm this finding.
METHODS: This is a secondary analysis of CARDIA, a multicenter cohort study. We included all women who had delivered a live infant. APOs were defined as a history of ever having a small-for-gestational-age infant, preterm birth, gestational diabetes mellitus, or hypertensive disorder of pregnancy. Women were categorized as having no, one or >1 pregnancy with any APOs. Outcomes included year 30 lung function, annual change in lung function from year 20-30 and presence of radiographic emphysema at year 25. Adjusted linear regression was used to evaluate associations between APO category and percent predicted forced expiratory volume in 1 s (FEV1) (ppFEV1), forced vital capacity (FVC) (ppFVC) and annual rate of decline in FEV1 and FVC from year 20-30.
RESULTS: Among 657 women, those with >1 pregnancy with APOs had a significantly lower year 30 ppFEV1 and greater annual decline in FEV1, compared to those without APOs (β co-efficient -2.45 %; 95 % CI, -4.87 to -0.03, and -6.67 ml/year; 95 % CI, -12.90 to -0.44, respectively). However, after adjustment for parity, findings were no longer statistically significant, raising the question of whether multiparity or recurrent pregnancies with APOs may be driving associations with lower FEV1.
CONCLUSIONS: A history of APOs may represent a novel, early indicator of worse lifetime maternal respiratory health, although larger studies accounting for multiparity and other important confounders are needed to confirm this finding.